Georgia's Online Cancer Information Center

Find A Clinical Trial

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Status
Active
Cancer Type
Lung Cancer
Trial Phase
Phase III
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT06646276
Protocol IDs
CA245-0001 (primary)
NCI-2025-03572
Study Sponsor
Bristol-Myers Squibb

Summary

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489
(Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus
Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy
in Participants with Extensive-Stage Small Cell Lung Cancer.

Eligibility

  1. Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
  2. Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
  3. Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system

Treatment Sites in Georgia

Northwest Georgia Oncology Centers (NGOC)


340 Kennestone Hospital Blvd.
Suite 100
Marietta, GA 3060


Study Coordinator:
Kristine Parker
470-267-1480

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.